
News|Podcasts|January 17, 2024
Patients Outcomes Impact (POI™): The Evolution of Measuring Patient-Centered Investment
Author(s)ZS Associates
Michael Shaw, JD, and Sharon Suchotliff, MPH, from ZS, discuss why measuring impact through a patient-centric lens is a business imperative for life sciences companies. They explore key considerations for a key challenge when thinking about impact for patients in the real world- the compliant measurement of non-promotional activities, results from an early ZS proof of concept to determine Patient Outcomes Impact (POI™) metrics, and discuss what you can do today to advance POI™ at your organization.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Trending on PharmExec
1
WHO Finalizes United States’ Withdrawal from Organization: Report
2
JP Morgan 2026 Wrap Up: Pharma Leaders Speak About the Conference and the State of the Industry
3
Novavax Enters $530 Million License Agreement with Pfizer for Vaccine Development
4
Janux Therapeutics Enters $850 Million Collaboration and Exclusive License Agreement with Bristol Myers Squibb to Develop Tumor-Activated Therapeutics
5




